AERIE PHARMACEUTICALS INC's ticker is AERI and the CUSIP is 00771V108. A total of 159 filers reported holding AERIE PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 2.23 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $810,272,000 | +110.8% | 53,554 | +4.5% | 0.00% | – |
Q2 2022 | $384,332,000 | -22.9% | 51,244 | -6.5% | 0.00% | – |
Q1 2022 | $498,617,000 | +29.6% | 54,793 | 0.0% | 0.00% | – |
Q4 2021 | $384,648,000 | -38.4% | 54,793 | 0.0% | 0.00% | – |
Q3 2021 | $624,640,000 | -28.7% | 54,793 | +0.1% | 0.00% | – |
Q2 2021 | $876,164,000 | +16.5% | 54,726 | +30.1% | 0.00% | – |
Q1 2021 | $751,898,000 | +32.3% | 42,076 | 0.0% | 0.00% | – |
Q4 2020 | $568,446,000 | +14.8% | 42,076 | 0.0% | 0.00% | – |
Q3 2020 | $495,234,000 | -22.4% | 42,076 | -2.7% | 0.00% | – |
Q2 2020 | $638,283,000 | +13.3% | 43,244 | +3.6% | 0.00% | – |
Q1 2020 | $563,249,000 | -38.9% | 41,722 | +9.4% | 0.00% | -100.0% |
Q4 2019 | $921,747,000 | +56.9% | 38,136 | +24.8% | 0.00% | – |
Q3 2019 | $587,382,000 | -26.0% | 30,561 | +13.8% | 0.00% | -100.0% |
Q2 2019 | $793,772,000 | -46.3% | 26,862 | -13.7% | 0.00% | 0.0% |
Q1 2019 | $1,479,342,000 | -60.4% | 31,144 | -69.9% | 0.00% | -66.7% |
Q4 2018 | $3,738,083,000 | -42.2% | 103,548 | -1.5% | 0.00% | -40.0% |
Q3 2018 | $6,472,598,000 | -3.8% | 105,160 | +5.6% | 0.01% | 0.0% |
Q2 2018 | $6,729,601,000 | +13.3% | 99,624 | -9.0% | 0.01% | 0.0% |
Q1 2018 | $5,937,230,000 | -13.5% | 109,442 | -4.7% | 0.01% | -16.7% |
Q4 2017 | $6,860,077,000 | +247.0% | 114,813 | +182.2% | 0.01% | +200.0% |
Q3 2017 | $1,977,193,000 | +119.2% | 40,683 | +137.1% | 0.00% | +100.0% |
Q2 2017 | $901,811,000 | +60.0% | 17,161 | +38.1% | 0.00% | 0.0% |
Q1 2017 | $563,701,000 | +236749.2% | 12,430 | +97.3% | 0.00% | – |
Q4 2016 | $238,000 | -46.2% | 6,300 | -46.2% | 0.00% | – |
Q3 2016 | $442,000 | +97.3% | 11,700 | +27.2% | 0.00% | – |
Q4 2015 | $224,000 | +7.7% | 9,200 | -21.4% | 0.00% | – |
Q3 2015 | $208,000 | -11.5% | 11,700 | -12.0% | 0.00% | – |
Q2 2015 | $235,000 | -7.5% | 13,300 | +64.2% | 0.00% | – |
Q1 2015 | $254,000 | – | 8,100 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management II, LLC | 906,317 | $16,078,000 | 4.88% |
Asymmetry Capital Management, L.P. | 85,834 | $1,523,000 | 3.39% |
March Altus Capital Management LP | 30,962 | $549,000 | 3.23% |
DAFNA Capital Management LLC | 165,669 | $2,939,000 | 2.92% |
Partner Investment Management, L.P. | 49,726 | $882,000 | 1.33% |
Boulegeris Investments, Inc. | 93,320 | $1,655,000 | 1.27% |
PFM Health Sciences, LP | 2,218,198 | $39,351,000 | 1.11% |
NORTHPOINTE CAPITAL LLC | 443,125 | $7,861,000 | 1.02% |
HARVEY CAPITAL MANAGEMENT INC | 121,850 | $2,161,000 | 0.86% |
Granite Point Capital Management, L.P. | 70,000 | $1,242,000 | 0.85% |